Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Systemic Treatment Options for Polycythemia Vera

March 22nd 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

Overview of MPNs

March 22nd 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

Dr. Rampal on the Role of JAK Inhibitors in Myelofibrosis

March 14th 2023

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

Dr. Mascarenhas on the Benefit of Fedratinib in Myelofibrosis

March 9th 2023

John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.

COVID-19 Vaccine Efficacy Decreases With Ruxolitinib Use in MPNs

March 9th 2023

Treatment with ruxolitinib impaired antibody responses to complete vaccination with the BNT162b2 SARS-CoV-2 vaccine in patients with myelofibrosis or polycythemia vera.

Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis

March 8th 2023

John Mascarenhas, MD, discusses the role of pacritinib in patients with myelofibrosis.

Ruxolitinib Demonstrates 6-Month Hematocrit Reduction in Polycythemia Vera

March 8th 2023

Treatment with ruxolitinib significantly reduced hematocrit levels and the number of yearly phlebotomies in patients with polycythemia vera, according to findings from a prespecified futility analysis of the phase 2b RuxoBEAT trial.

Dr. Jain on Unmet Needs in Patients with Myelofibrosis Undergoing Allo-SCT

March 6th 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Incyte to Discontinue Phase 3 LIMBER-304 Trial of Parsaclisib Plus Ruxolitinib in Myelofibrosis

March 6th 2023

The phase 3 LIMBER-304 trial evaluating parsaclisib plus ruxolitinib in patients with myelofibrosis will be discontinued after results of a preplanned interim analysis indicated that the study is unlikely to meet its primary end point of targeted reduction in spleen volume in the intent-to-treat population.

MDS Options Are Poised to Expand Across Risk Groups

March 6th 2023

Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes.

Dr. Jain on Transplantation from Haploidentical Donors in Myelofibrosis

February 27th 2023

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Dr. Kuykendall on the Investigation of Navitoclax Plus Ruxolitinib in Myelofibrosis

February 15th 2023

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

Dr. Patel on Post-ASCT Complications in Myelofibrosis

February 14th 2023

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

Dr. Mascarenhas on the Evolution of JAK Inhibitors in Myelofibrosis

February 7th 2023

John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.

Dr. Kuykendall on the Evaluation of Momelotinib in Myelofibrosis

February 3rd 2023

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine Neoplasms

January 31st 2023

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Phase 1/2 Trial Pauses Enrollment for Evaluation of MGTA-117 in AML/MDS After Patient Death

January 26th 2023

Magenta Therapeutics has voluntarily paused enrollment for a phase 1/2 trial evaluating the antibody-drug conjugate MGTA-117 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome following the death of a patient.

FDA Grants Priority Review to Avapritinib in Indolent Systemic Mastocytosis

January 23rd 2023

The FDA has granted a priority review to the supplemental new drug application (sNDA) to avapritinib for the treatment of adult patients with indolent systemic mastocytosis.

Ruxolitinib/Pegylated Interferon Alpha 2a Reduces Spleen Length in Myelofibrosis

January 23rd 2023

First-line ruxolitinib plus pegylated interferon alpha 2a demonstrated durable spleen volume reduction in patients with myelofibrosis.

TP-3654 Showcases Early Signs of Tolerability, Clinical Activity in Myelofibrosis

January 17th 2023

The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.